FDA Drug Shortage List Duration
Regulatory
Buy side
Sell side
Feasibility
Extracted facts
Research report
Demand Research Report: FDA Drug Shortage List Duration
Generated: 2026-04-19T06:24:43.053374 Event ID: drug_shortage_duration_parametric
Executive Summary
| Metric | Value |
|---|---|
| Verdict | MODERATE_DEMAND |
| Confidence | 65% |
| Companies Exposed | 0 |
Healthcare distributors face material but indirect exposure to FDA drug shortages. The research reveals that drug shortages are a persistent, costly problem—Vizient surveys show hospitals incur $894M annually in labor costs alone managing shortages (up 150% in 5 years). The 'Big 3' distributors (McKesson, Cencora, Cardinal Health) control 90%+ of pharmaceutical distribution with combined revenues exceeding $900B annually, but their business model insulates them from direct financial penalties tied to shortage duration.
The critical finding: distributors operate as intermediaries sourcing from manufacturers, not guarantors of supply. While shortages create operational friction—emergency sourcing, customer service burdens, potential margin compression on alternatives—SEC filings from all three major distributors contain NO specific risk factor disclosures about drug shortages causing financial penalties or revenue loss. Generic drugs (most prone to shortages) represent low-margin, high-volume business where distributors have limited pricing power. The 2023 carboplatin/cisplatin shortage affected 90%+ of cancer centers yet caused no material stock movements for distributors.
Demand exists but is moderate: Hospitals/GPOs bear the primary financial burden and would be natural hedgers. Distributors might purchase shortage contracts defensively (protect customer relationships, reduce service costs) rather than for direct P&L protection. The parametric structure (days on shortage list) aligns with the FDA's public data source, making resolution straightforward. However, without contractual obligations tying distributor payments to shortage duration or evidence of hedging activity, this represents opportunistic rather than urgent demand.
Company-by-Company Analysis
McKesson Corporation (MCK)
Exposure: As the largest U.S. pharmaceutical distributor, McKesson sources and distributes pharmaceuticals including generic injectables frequently subject to FDA shortages. During shortages, must engage in costly emergency sourcing, customer service interventions, and potential margin compression when substituting higher-cost alternatives.
Quantified Impact: FY2025 revenue: $368.6B total, ~$300B+ pharmaceutical distribution. Operates on thin margins (typically 1-3% operating margin on pharma distribution). Generic drugs represent significant volume but lowest-margin business. No quantified shortage impact disclosed.
10-K Risk Factor Quote (2025-05-08):
No specific drug shortage risk factors identified in available 10-K filings. Standard supply chain risk language present but does not mention FDA shortage list or financial penalties tied to product availability.
Current Hedging: No disclosed hedging mechanisms for drug shortage risk. Company published white papers acknowledging shortage challenges but describing them as industry-wide systemic issues requiring policy solutions, not financial hedging.
Cardinal Health, Inc. (CAH)
Exposure: Major pharmaceutical distributor with significant generic drug distribution. Pharmaceutical segment represents majority of business. Subject to same shortage dynamics as peers—emergency sourcing costs, customer relationship pressure, operational complexity during shortages.
Quantified Impact: FY2025: Pharmaceutical segment revenue ~$200B+ of total $229.1B revenue. Operates on low single-digit operating margins in pharma segment. Publicly stated commitment to addressing shortages but no quantified financial impact.
10-K Risk Factor Quote (2025-08-15):
No specific FDA drug shortage risk factors found in recent 10-K filings. Standard manufacturer/supplier disruption language exists but does not tie to shortage duration or financial penalties.
Current Hedging: Published systematic solutions papers on drug shortages, focusing on policy advocacy and supply chain resilience. No financial hedging instruments disclosed. Participates in industry coalitions addressing shortage root causes.
Cencora, Inc. (formerly AmerisourceBergen) (COR)
Exposure: Third member of 'Big 3' pharmaceutical distributors. Specialty pharmaceutical focus may provide some insulation from generic shortage impacts, but still distributes generic injectables. Serves oncology practices heavily affected by recent shortages.
Quantified Impact: FY2025 revenue: $321.3B total, U.S. Healthcare Solutions segment ~$285B. Company emphasizes specialty pharma and higher-margin products, potentially reducing generic shortage exposure relative to peers. No disclosed shortage-specific financial impacts.
10-K Risk Factor Quote (2025-11-06):
No FDA drug shortage-specific risk factors identified in recent 10-K filings. Standard supplier and product availability risk language present but does not reference shortage list duration or contractual penalties.
Current Hedging: No disclosed hedging for drug shortage risk. Company strategy emphasizes diversification into specialty pharmaceuticals and value-added services, which may provide natural hedge against generic shortage volatility.
Premier, Inc. (GPO) (PINC)
Exposure: Group Purchasing Organization serving 4,400+ hospitals and health systems. GPO contracts often include supply assurance provisions. When distributors fail to supply contracted products due to shortages, GPO members face higher costs sourcing alternatives, creating reputational and contractual pressure.
Quantified Impact: GPO facilitates ~$69B in annual purchasing volume. Member hospitals report $894M in annual labor costs managing shortages. GPO reputation depends on supply reliability, creating indirect exposure to shortage events.
10-K Risk Factor Quote (N/A):
Not available in search results—Premier is privately held/operates as limited partnership.
Current Hedging: Develops 'supply assurance' programs with distributors and manufacturers but these are contractual arrangements, not financial hedges. Published extensive research on shortage impacts to member organizations.
Historical Events
| Date | Event | Impact | Companies |
|---|---|---|---|
| 2023-02-01 | Carboplatin/Cisplatin chemotherapy shortage - FDA ... | No material stock impact on distributors observed. MCK, CAH, COR stocks did not move significantly during peak shortage period (Feb-Jun 2023). Healthcare providers bore primary cost burden. | MCK, CAH, COR... |
| 2023-06-07 | NCCN survey reveals 93% of cancer centers experien... | Minimal distributor stock impact. ASCO analysis later showed shortage increased treatment costs significantly but distributors passed costs through supply chain. | Treatment centers, distributors, patients |
| 2024-07-09 | FDA marks cisplatin shortage as 'resolved' after 1... | No measurable stock response to resolution announcement, suggesting market did not view shortage as material financial event for distributors. | All pharmaceutical distributors, oncology providers |
| 2025-04-16 | Johnson & Johnson warns of drug and device shortag... | Healthcare stocks moved: UNH -22.19%, HUM -7.78%, CNC -2.54%, CVS -2.37%. Notably, pharmaceutical distributors NOT prominently mentioned, suggesting shortage risk viewed as manufacturer/payer issue. | UNH, CVS, CNC... |
| 2025-06-17 | Vizient releases updated survey showing drug short... | No direct distributor stock impact. Confirms shortage costs falling on healthcare providers, not distributors. Demonstrates escalating financial burden creating potential hedging demand. | Hospitals, health systems, GPOs |
Market Sizing
| Metric | Value |
|---|---|
| Companies Exposed | 3 |
| Combined Market Cap | ~$150B (MCK ~$75B, COR ~$45B, CAH ~$30B as of 2025) |
| Annual Revenue at Risk | Difficult to quantify direct revenue at risk. Combined pharmaceutical distribution revenue ~$900B+ annually, but shortage impact is operational cost and margin compression, not revenue loss. Estimated operational burden: $50-100M annually across Big 3 in emergency sourcing, customer service, inventory management during shortages. Indirect risk: customer relationship damage, potential contract penalties (undisclosed amounts). |
Methodology: Market cap from public trading data. Revenue from FY2025 10-K filings and earnings releases. Operational cost estimates based on: (1) Hospital labor costs of $894M annually (Vizient) suggesting distributor operational costs in tens of millions; (2) Distributor operating margins of 1-3% on ~$900B revenue = $9-27B annual operating income, making $50-100M shortage costs 0.2-1% of operating income; (3) No disclosed financial penalties or quantified shortage impacts in any 10-K filings.
Proposed Contract Structure
| Attribute | Value |
|---|---|
| Type | Parametric |
| Trigger | Number of days a specified high-revenue drug (defined by NDC or generic name) remains on FDA Drug Shortage Database, capped at 365 days per drug per annual period. Payout structure: $X per day after day 30, increasing tiers for 60+ days, 90+ days, 180+ days to reflect escalating sourcing difficulty. |
| Resolution Source | FDA Drug Shortage Database at accessdata.fda.gov/scripts/drugshortages/default.cfm - publicly available, updated daily by FDA Drug Shortages Staff. Database includes drug name, active ingredient, current status (Active Shortage, Resolved, Discontinued), reason for shortage, and estimated resolution date. Well-established, authoritative source used by hospitals, distributors, and manufacturers. |
| Settlement | Binary determination: Is drug X on active shortage list on date Y? Count consecutive days from first shortage listing to resolution. Settlement triggered quarterly or annually based on total days accumulated. Cash settlement T+5 after period end. Alternative: Monthly mini-settlements for drugs exceeding 90-day threshold to provide liquidity during extended shortages. |
Existing Hedging Alternatives
No commercial hedging products exist specifically for drug shortage risk. Existing approaches are contractual, not financial: (1) Supply Assurance Contracts: GPOs negotiate supply commitments with distributors/manufacturers, but these are service-level agreements with operational penalties, not transferable risk instruments. (2) Inventory Buffering: Distributors and hospitals maintain safety stock, but FDA and DEA regulations limit stockpiling of many drugs, especially controlled substances. Capital intensive and doesn't address extended shortages. (3) Multi-Source Contracting: Hospitals contract with multiple distributors, but when shortage is manufacturer-level (most common), all distributors affected equally. (4) Insurance: No pharmaceutical shortage insurance products exist. General business interruption insurance excludes supply chain disruptions outside company's control. (5) Manufacturer Agreements: Some high-value drugs have direct manufacturer-hospital contracts with supply guarantees, but these are limited to specialty products, not generics where shortages concentrate.
Why insufficient: All existing approaches are operational/contractual, not financial hedges. They don't provide liquidity during shortage events or compensate for margin compression when sourcing expensive alternatives. None transfer the duration risk of shortages. The parametric structure Prophet offers would be first financial product addressing this gap.
Supporting Evidence
10K Risk Factor
🔴 McKesson 10-K FY2025
- Company: McKesson
- Date: 2025-05-08
- No specific drug shortage risk factors identified. Standard supply chain risk language present: discussions of manufacturer supply disruptions, product recalls, regulatory issues. No mention of FDA shortage list, financial penalties tied to product unavailability, or contractual obligations during shortages.
- Source
News
🟢 Vizient Survey 2025
- Date: 2025-06-17
- Drug shortages cost hospitals nearly $900M annually in labor expenses—a 150% increase from $360M in 2019. Survey reflects additional staffing for shortage management, alternative product research, clinical protocol modifications, and patient communication.
- Source
🟡 McKesson White Paper on Drug Shortages
- Company: McKesson
- Date: 2024
- McKesson acknowledges drug shortages as industrywide problem requiring 'multitude of issues contributing to drug shortages' but frames as policy issue, not insurable risk. States 'no distributor is immune to the inventory challenges they pose' but describes impact as operational, not financial penalty.
- Source
🟢 NCCN Survey Results
- Date: 2023-06-07
- Survey of cancer centers showed 93% experiencing carboplatin shortages, 70% experiencing cisplatin shortages. Centers reported treatment delays, use of alternative regimens with different toxicity profiles, and significantly increased costs. Shortage persisted despite distributor emergency sourcing efforts.
- Source
🟢 ASPE Report to Congress
- Date: 2025-01-08
- HHS analysis of drug shortages shows sterile injectables consistently most vulnerable category, with shortages persisting average 303 days. Generic drugs represent majority of shortage events due to limited manufacturer competition and thin profit margins.
- Source
🟢 ASCO Post
- Date: 2024-09
- Cisplatin shortage led to treatment alternatives for head and neck cancer, significantly increasing cost. Study documented financial burden of alternative regimens but costs primarily borne by healthcare systems and payers, not distributors who operate on pass-through model.
- Source
🟢 Drug Channels Institute Report
- Company: Industry
- Date: 2023-10
- Big 3 distributors (McKesson, Cencora, Cardinal) control 92% of pharmaceutical distribution market with combined revenues exceeding $900B. Operate on razor-thin margins (1-3% operating margin) in pharmaceutical distribution, with profit coming from fee-for-service and generic sourcing spreads, not product margin.
- Source
🟡 Premier Blog
- Company: Premier (GPO)
- Date: 2026-01
- Pharmacy supply chain described as 'fault line' for health systems in 2026. GPO emphasizes pharmacy 'no longer a support function' but strategic priority. Suggests supply reliability becoming competitive differentiator, creating potential value for shortage hedging products.
- Source
🟡 FDA Report to Congress
- Date: 2025
- FDA reports 195 active drug shortages as of February 2026 (down from peak). Sterile injectables remain most problematic category. Root causes identified: manufacturing quality issues, limited competition, economic factors making generic production unprofitable. No mention of distributor liability or penalties.
- Source
Stock Event
🟢 Historical stock analysis
- Company: MCK, CAH, COR
- Date: 2023-2024
- Analysis of major shortage events (carboplatin/cisplatin 2023, various sterile injectables 2022-2024) shows no significant stock price movements for pharmaceutical distributors. Average impact <1% during peak shortage announcements, suggesting market does not view as material financial risk.
Detailed Analysis
The verdict of MODERATE_DEMAND with 65% confidence reflects several competing factors:
STRONG EVIDENCE FOR DEMAND: (1) Drug shortages are persistent, worsening problem with quantified financial impacts—$894M annually in hospital labor costs alone, up 150% in 5 years. (2) Sterile injectable shortages affect high-value clinical areas (oncology, critical care) where supply failures create urgent patient care issues and reputational damage. (3) No existing financial hedging products exist, creating clear market gap. (4) FDA data source is authoritative, public, and updated daily—excellent for parametric contract resolution. (5) GPO and hospital procurement professionals express increasing concern about shortage impacts on operations and patient care.
EVIDENCE LIMITING DEMAND: (1) Pharmaceutical distributors, the most obvious buyers, show NO evidence of viewing shortages as material financial risk. Zero distributor stock movements during major shortage events. No risk factor disclosures in 10-Ks. No disclosed hedging activity. (2) Business model insulation: Distributors operate as intermediaries on thin margins with pass-through economics. They don't absorb shortage costs—they pass them to customers or manufacturers. (3) Shortage impact is operational (customer service burden, emergency sourcing complexity) rather than direct P&L hit that would justify hedging spend. (4) Generic drugs (most shortage-prone) are lowest-margin business for distributors—limited financial exposure per SKU. (5) Industry white papers frame shortages as policy problem requiring regulatory solutions, not financial risk requiring hedging.
WHO WOULD BUY: Primary demand likely comes from: (1) Hospital systems and large health networks bearing direct costs—labor, alternative drug expenses, patient care disruption. They have clearest financial exposure but may lack sophistication for derivatives. (2) GPOs seeking to backstop supply commitments to members—reputational protection. (3) Distributors might buy defensively to protect major customer relationships or reduce service costs, but this is tertiary motivation. (4) Specialty distributors focused on oncology/critical care where shortage impacts most severe.
CONTRACT STRUCTURE STRENGTHS: Parametric design based on FDA shortage list is elegant—objective, transparent, no moral hazard. Days-on-list directly correlates with operational burden and cost escalation. Capped at 365 days prevents tail risk for sellers while providing meaningful protection for buyers. Tiered payouts (30/60/90/180 days) match escalating sourcing difficulty.
WEAKNESSES: (1) Basis risk: Shortage declaration doesn't perfectly correlate with financial impact. Some shortages resolved quickly, others linger with intermittent availability. (2) Product specification: Need precise definition of 'high-revenue drugs'—NDC-level specificity or therapeutic category? (3) Pricing challenge: Without historical loss data or evidence of willingness-to-pay, difficult to establish premium levels. (4) Limited comparable products for market education.
CONCLUSION: Moderate demand exists, primarily from healthcare providers and GPOs rather than distributors. Market needs education on using financial tools for supply chain risk. Success depends on: (1) Targeting hospital CFOs and supply chain VPs directly, not just distributor procurement. (2) Demonstrating ROI using Vizient cost data. (3) Starting with pilot customers in high-exposure specialties (oncology networks, children's hospitals dependent on pediatric formulations). (4) Potential regulatory tailwind if CMS or other payers recognize shortage hedging as allowable cost. Without evidence of actual hedging demand or material financial losses disclosed by distributors, rating cannot exceed MODERATE.
Report generated by Prophet Heidi Research Pipeline